Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Agusti A, Faner R, Donaldson G, et al. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. Eur Respir J 2019;53(3):1900217.
2. Hopkinson NS, Bush A, Allinson JP, et al. Early life exposures and the development of chronic obstructive pulmonary disease across the life course. Am J Respir Crit Care Med 2024;210(5):572–80.
3. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022;400(10356):921–72.
4. Murgia N, Gambelunghe A. Occupational COPD–The most under-recognized occupational lung disease? Respirology 2022;27(6):399–410.
5. Landrigan PJ, Fuller R, Acosta NJR, et al. The Lancet Commission on pollution and health. Lancet 2018;391(10119):462–512.
6. Australian Commission on Safety and Quality in Health Care. Chronic Obstructive Pulmonary Disease Clinical Care Standard. October 2024.
7. Myers LC, Quint JK, Hawkins NM, et al. A research agenda to improve outcomes in patients with chronic obstructive pulmonary disease and cardiovascular disease: An official American Thoracic Society research statement. Am J Respir Crit Care Med 2024;210(6):715–29.
8. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report.
9. Cushnahan A, Leaver B, Dunne B, et al. Environmental impact of pressurised metered dose inhalers versus dry powder and soft mist inhalers at a tertiary Melbourne hospital. Intern Med J 2024;54(11):1898–02.
10. Health New Zealand. Immunisation Handbook 2025, version 1.
11. Landers A, Wiseman R, Pitama S, Beckert L. Severe COPD and the transition to a palliative approach. Breathe (Sheff) 2017;13(4):310–16.
12. Maddocks M, Lovell N, Booth S, et al. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet 2017;390(10098):988–1002.
13. Williams PJ, Buttery SC, Laverty AA, Hopkinson NS. Lung disease and social justice: Chronic obstructive pulmonary disease as a manifestation of structural violence. Am J Respir Crit Care Med 2024;209(8):938–46.
14. Landers A, Pitama SG, Green SC, Beckert L. Policy, system and service design influence on healthcare inequities for people with end-of-life chronic obstructive airways disease, their support people and health professionals. BMC Health Serv Res 2024;24(1):1190.
15. Royal Australasian College of Physicians. Professional Practice Framework.
16. Soriano JB, Lumbreras S, Celli BR, Jenkins CR. I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health. Eur Respir J 2024;64(1):2400919.